Globus Medical stock barely flinched after earnings, up about 1.6% to US$82.37, yet the quarter was anything but quiet. The musculoskeletal specialist delivered record non‑GAAP earnings per share and a Q2 adjusted EBITDA margin in the mid 30s, a powerful signal of margin strength in a sector where pricing and hospital budgets often squeeze returns.
Investors came into this print with a story centered on long term earnings quality and a relatively modest valuation. This quarter put the focus squarely on how far Globus Medical can push margins while still funding growth in its spine and robotics platforms.
Love Globus Medical's strong margins but want more stocks with that same earnings power and balance sheet support? Check out the list of solid balance sheet and fundamentals stocks (49 results).
Q2 2026 Earnings Summary
- Revenue (Q2 2026 vs Q2 2025): US$789.6 million vs. US$745.3 million (up 5.9%)
- Net Income (Excl. Extra Items, Q2 2026 vs Q2 2025): US$151.6 million vs. US$202.8 million (down 25.2%)
- Basic EPS (Q2 2026 vs Q2 2025): US$1.12 vs. US$1.50 (down 25.2%)
- Adjusted EBITDA Margin (Q2 2026 vs Q2 2025): 35.4% vs. 28.0% (up 740 basis points)
If you are tired of staring at lengthy earnings tables and margin figures for Globus Medical, get a clear visual overview of its profitability and earnings quality in an easy-to-scan set of charts with our company report for Globus Medical.
Globus Medical’s Margin Story Clears Key Hurdles
Supporters of Globus Medical argue that the real story is margin scale from NuVasive and Nevro integration, automation, and a higher quality revenue mix. Q2 goes a long way toward proving that. Adjusted EBITDA margin reached 35.4%, roughly in line with the “mid 30s” ambition that management has been talking about, while adjusted gross margin moved to 69.4%. That lines up with management’s plan to move back toward mid 70s over time.
The bullish view also leans on robotics and software driven recurring revenue. On the surface, Enabling Technologies revenue fell 26% year on year, which would usually pressure that narrative. However, Excelsius placements grew about 25% on a sold, leased, or rented basis, consistent with the shift to leasing models that are intended to link robots more tightly to implant and disposable pull through.
Compare Globus Medical’s margin progress and robotics push with how institutional analysts are reacting right now. See the consensus price target analysis for Globus Medical to check whether the street’s targets are keeping pace with the story.Globus Medical Bears Still See Integration Gaps
The core bearish worry on Globus Medical is that integration, Nevro execution, and robotics adoption would lag enough to cap earnings quality despite strong reported margins. This quarter does not fully clear that bar. Nevro sales declined about 14% year on year and were flat to down sequentially, and management explicitly tied the full year outlook to a rebound in trial volumes by late Q4. That keeps integration and acquired growth firmly in the “prove it” bucket.
Bears have also flagged that robotics uptake could be slower and more volatile than the story suggests. Enabling Technologies revenue fell 26% year on year as the company leaned harder into leasing. Excelsius placements grew about 25%, yet the revenue profile is now lumpier and more back end loaded into implants and disposables. Combined with tough H2 comparables and region specific disruptions, the quarter leaves several operational milestones still unmet.
With earnings growth outpacing revenue and margin expansion doing the heavy lifting, it is fair to ask whether Globus Medical’s cash generation, debt profile, and liquidity are strong enough to support this path. Check the full solvency breakdown in our financial health analysis of Globus Medical stock.Stay Ahead With Simply Wall St
If Globus Medical's margin profile and integration story have you watching for the right entry point, register for free with Simply Wall St and add it to your Watchlist to track price against fair value and key fundamentals. After you build a position, keep your focus on what really matters by managing your holdings through the Portfolio Command Center that highlights only the most important developments. Round this out by tapping into crowd insights and market sentiment in the Community to see how other investors are reacting to new data on Globus Medical. By surfacing potential catalysts and risks early, Simply Wall St helps you move faster and stay ahead of the market.
Seeking Alternatives Beyond Globus Medical?
Fresh ideas can move fast. Some stocks are building breakout momentum while others are still under the radar for now. Check them before the data goes stale and aim to get in early.
- Spot quieter compounders before they start flying by scanning a curated set of resilient companies in the 78 resilient stocks with low risk scores.
- Chase real cash flow, not hype, by focusing on 68 profitable AI stocks that aren't just burning cash where companies combine AI exposure with current profitability instead of relying on long-term projections.
- Review potential sector opportunities by exploring 36 power grid technology and infrastructure stocks which highlights companies involved in grid projects, electrification efforts, and long-term infrastructure initiatives.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com